Malcolm Moore, PhD, MD, FRCP (C)
Director, Bras Drug Development Program, PMH
Head, Department of Medical Oncology & Haematology
KY Ho Chair in Prostate Cancer Research
Senior Scientist, Division of Experimental Therapeutics, OCI
Professor, Department of Medicine & Pharmacology University of Toronto

The Robert & Maggie Bras and Family New Drug Development Program at Princess Margaret Cancer Centre is an exciting new initiative focusing on phase I and II studies of innovative drugs with a strong emphasis on pharmacokinetics and correlative studies. It involves a collaborative and multidisciplinary approach and is strategically designed to ensure the rapid completion of high quality studies.

The Program is led by Drs. Malcolm Moore, Amit Oza and Lillian Siu. The Director, Dr. Moore, is a Professor of Medicine and Pharmacology in the Department of Medical Oncology and Hematology at Princess Margaret Cancer Centre, University of Toronto and a Senior Scientist in the Division of Experimental Therapeutics at the Ontario Cancer Institute.

He is chair of the GI Cancer Program at The Princess Margaret and was recently appointed Chair of the GI committee for National Cancer Institute of Canada [NCIC]. Dr Moore is the Director of The Robert & Maggie Bras and Family New Drug Development Program and heads the Phase II Consortium, an alliance of 3 hospitals, The Princess Margaret, Hamilton and London Regional Cancer Centres that won a contract with NCI ensuring access to new NCI anti-cancer drugs. His major interest over the past 10 years has been innovative drug development for cancer therapy.

He has been a principal investigator for many phase I, II and III studies in gastrointestinal and genitourinary cancer supported by NCI, NCIC and the pharmaceutical industry. He has been instrumental in the development of a number of agents that have subsequently been approved for clinical usage such as mitoxantrone in hormone refractory prostate cancer and gemcitabine in both pancreatic and urothelial cancer. Dr Moore has 90 peer reviewed publications and has given over 100 invited lectures.